CliffBio
small molecule

ISTODAX

ROMIDEPSIN

Loss of exclusivity—loss of exclusivity
CompanyBristol Myers Squibb →See this company's full patent-cliff portfolio

Drug detail

Brand nameISTODAX
Active ingredientROMIDEPSIN
Strength10MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2009
Marketing statusRX

More from Bristol Myers Squibb

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ISTODAX patent cliff — loss of exclusivity — | CliffBio